Dr. Owen Winsett of the
Breast Center of Austin
is one of the first physicians in the nation to make the
predictive risk test available to his patients. Clinically validated BREVAGen is the latest advance in assessing a woman’s unique risk of developing non-familial or sporadic breast cancer.
“Seventy to eighty percent of women who get breast cancer do not have familial risk indicators. Now, for the first time, BREVAGen allows me to make informed decisions for those patients with non-familial or sporadic risk of breast cancer based on their personal history and genetics, not simply a statistical risk score,” said Owen Winsett, M.D. “BREVAGen test results make it easier for my patients and me to decide on an appropriate level of monitoring and, if necessary, a more intensive surveillance plan of action including MRI or chemoprevention.”
BREVAGen is a clinically validated predictive risk test that more accurately identifies a woman’s unique risk of developing sporadic, estrogen-positive breast cancer. BREVAGen combines a woman’s clinical history of prolonged estrogen exposure (Gail score) with identified genetic markers to determine five-year and lifetime risk assessments of developing breast cancer.
BREVAGen is supplied by Phenogen Sciences, a subsidiary of Genetic Technologies Limited (NASDAQ: GENE). For more information about BREVAGen, contact Alma Avila at (512) 451-5788 or
How BREVAGen Works
The BREVAGen predictive risk test is administered in a physician’s office using a simple, non-invasive “oral-swab”. Following analysis in a CLIA-certified laboratory, physicians receive a comprehensive genetic risk prediction report to review with the patient. The patient’s risk of breast cancer is calculated by combining their relative risk score from seven genetic markers, called SNPs (single nucleotide polymorphisms), with their Gail score (factors that comprise the patient’s clinical make-up including current age, age at menarche, age at live first birth, race/ethnicity, etc).